Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 418

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 3
Chunk 418
---
 
     -  
     5,738 
  
    Total liabilities 
     10,986  
     7,681 

    Commitments and contingencies (see note 15) 
     - 
     - 

    Stockholders’ deficit 

    Common stock, par value $0.0001;
250,000,000 shares authorized at December
31, 2024 and December 31, 2023, respectively, 1,384,801
shares and 738,295 shares issued
and outstanding at December 31, 2024 and December 31, 2023, respectively 
     14  
     7 
  
    Preferred stock, par value $0.0001; 1,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; nil shares issued and outstanding at December 31, 2024 and December 31, 2023 
     -  
     - 
  
    Additional paid-in capital 
     21,880  
     10,424 
  
    Accumulated deficit 
     (29,101) 
     (11,299)
  
    Accumulated other comprehensive income 
     414  
     411 
  
    Total stockholders’ deficit 
     (6,793) 
     (457)
  
    Total liabilities and stockholders’ deficit 
    $4,193  
    $7,224 

The
accompanying notes are an integral part of these consolidated financial statements.

F-3

CONDUIT
PHARMACEUTICALS INC.

CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(in
thousands, except share amounts and per share data)

    2024  
    2023 

    Year Ended December 31, 

    2024  
    2023 
  
    Operating expenses: 

    Research and development expenses 
    $3,378  
    $90 
  
    General and administrative expenses 
     12,041  
     5,172 
  
    Total operating costs and expenses 
     15,419  
     5,262 
  
    Operating loss 
     (15,419) 
     (5,262)
  
    Other income (expenses): 

    Other income